Strategy

Using prescription digital therapeutics can lead to better outcomes for patients, making them a win-win for pharma and patients.

Regardless of engagement mode pursued, personalization is the key.

Sunil Verma, SVP, Global Head of Oncology, Medical, AstraZeneca discusses how the Medical Affairs role will become more strategic and effective with data.

Looking at corporate value through a portfolio lens provides an astute and reliable path to genuine value creation.

Global medical affairs teams seek better support to manage relationships with key opinion leaders—and find that balance between patient needs, scientific objectives, and the interest areas of KOLs.

Pharm Exec spoke with Skalicky about new ways that life sciences companies are engaging with outsourcing.

Author Deepa Purushothaman discusses the progress of women and women of color in corporate America.

Pete O'Heeron, founder, chairman, and CEO of FibroBiologics, explains the key principles that biotechnology companies should follow.

Michael Ku, VP of global clinical supply at Pfizer, shares insights for the c-suite as well as reveals behind-the-scenes insight into Pfizer’s ability to deliver a COVID-19 vaccine swiftly.

A clearer understanding of the Inflation Reduction Act’s implications is needed for manufacturers to plot a successful course forward.

Rocket Pharmaceutical's CEO and CTO spoke with Pharm Exec about adding a new position to the company's C-suite.

Life sciences companies are collaborating more with technology enterprises, universities, and other groups, which is changing the landscape of the industry.

Barnes discusses alternative reimbursement plans for expensive, one-off therapies.

How pharma companies can make sure their corporate strategy in ESG is appealing to younger generations—and aligns with the issues this large segment of sustainability investors care about most.

Corrigan discusses the importance of a patient-centric approach.

Patients with Crohn's disease and ulcerative colitis face a high disease burden.

With heightened government scrutiny on educational forums, biopharma manufacturers need a sound framework that demonstrates they are following best practices.

A proactive and tailored compliance department—with the nimbleness to adapt strategies on the fly—is a critical shield for life sciences companies during government investigations.

As director of corporate strategy for Novartis, Kamenska defines direction for the company’s overall enterprise. Here, she discusses how the pandemic and recent market events are shaping these strategies.

Employees must be able to retain information and remain engaged to keep pace with highly regulated industry.

We may be only at the beginning of outcome-measured, value-based healthcare, but this is a chance for pharma organizations to show their mettle as roles are redefined and definitions of ‘value’ are agreed, says Gérard Klop of Vintura.

Automated risk management and improved regulatory compliance among opportunities offered by case collection.

Recent increases in employee burnout and turnover must be addressed.

COVID-19 pandemic has accelerated raised expectations for medical information professionals.

Moorman discusses critical aspects of key account management in pharma.

Recent explosion at Zaporizhzhia nuclear power plant in Ukraine shows how pharma industry can pull together and take action in the face of adversity.

Pandemic workforce trends continue to create challenges for pharma.

Improvements in R&D, manufacturing, and data sharing will extend platform’s reach.

Optimally designed SSO program can allow companies to deliver therapies to patients faster and at a more affordable cost.

Recent advances from COVID-19 vaccine development put pharma in place to further grow relationship with patients.